Publications by Dr Evan Mulligan - ePrints

Browsing publications by Dr Evan Mulligan.

Newcastle Authors	Title	Year
Dr Evan Mulligan Dr Susan Tudhope Dr Jill Hunter Sarah Elliott Dr Jonathan Wallis et al.	Expression and Activity of the NF-κB Subunits in Chronic Lymphocytic Leukaemia: A Role for RelB and Non-Canonical Signalling	2023
Dr Elaine Willmore Dr Aaron Ions Gardner Dr Susan Tudhope Belinda Murtani Jessica Caffry et al.	Novel small molecule IKK alpha inhibitors inhibit non- canonical NF-kappa B signaling and survival of primary CLL cells	2015
Dr Ashleigh Herriott Dr Susan Tudhope Gesa Junge Natalie Rodrigues Dr Miranda Patterson et al.	PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in Chronic Lymphocytic Leukaemia	2015
Dr Asima Mukhopadhyay Michelle Dixon Dr Evan Mulligan James Murray Professor Nicola Curtin et al.	Evaluation of different methods to assess homologous recombination status and sensitivity to parp inhibitors in ovarian cancer	2014
Professor Ruth Plummer Dr Evan Mulligan Professor Nicola Curtin Professor Alan Calvert	A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation	2013
Dr Susan Tudhope Dr Evan Mulligan Dr Jill Hunter Dr Helen Marr Professor barbara Durkacz et al.	P B S-1086, a "Pan-Rel" Inhibitor, Decreases Viability of Chronic Lymphocytic Leukemia Cells	2012
Dr sarah Johnson Clark Crawford Dr Evan Mulligan Dr Jonathan Wallis Dr Tryfonia Mainou-Fowler et al.	Mitoxantrone in combination with an inhibitor of DNA-dependent kinase: a potential therapy for high risk B-cell chronic lymphocytic leukaemia	2011
Dr Yvette Drew Dr Evan Mulligan Wan Vong Huw Thomas Suzanne Kyle et al.	Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2	2011
Huw Thomas Suzanne Kyle Rafal Zur Dr Evan Mulligan Professor Nicola Curtin et al.	6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance	2010
Dr Elaine Willmore Dr Evan Mulligan Dr Sarah Elliott Professor barbara Durkacz	ATM Mutant Chronic Lymphocytic Leukaemia Cells are Chemosensitized by Inhibition of DNA Dependent Protein Kinase	2010
Rachel Daniel Dr Agata Rozanska Dr Evan Mulligan Dr Yvette Drew Huw Thomas et al.	Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699	2010
Dr Evan Mulligan Dr Natalie Ferry Professor Angharad MR Gatehouse	Characterisation of adult green lacewing (Chrysoperla carnea) digestive physiology: impact of a cysteine protease inhibito and a synthetic pyrethroid	2010
Dr Evan Mulligan Arabella Baird Dr Jonathan Wallis Dr Stephany Veuger Professor barbara Durkacz et al.	Relationships Between Aberrant Activity of the NF-kappa B Subunits and Outcome In Chronic Lymphocytic Leukemia: The Dual Role of DNA Damage Sensor Enzymes	2010
Dr Agata Rozanska Dr Evan Mulligan Huw Thomas Deborah Castelbuono Professor Deborah Tweddle et al.	[abstract] Central nervous system (CNS) penetration, poly-ADP ribose polymerase (PARP) inhibition and enhancement of temozolomide activity against childhood medulloblastoma by AG-014699	2009
Dr Evan Mulligan Tomasz Zaremba Dr Yvette Drew Professor Ruth Plummer Professor Nicola Curtin et al.	[abstract] Validated sensitive immunological determination of PARP-1 protein levels and activity in cultured cells and human lymphocytes	2009
Dr Evan Mulligan Professor Nicola Curtin Professor Ruth Plummer	Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines	2009
Dr Agata Rozanska Huw Thomas Dr Evan Mulligan Dr Yvette Drew Deborah Castelbuono et al.	Inhibition of Poly (ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma	2009
Dr Natalie Ferry Dr Evan Mulligan Professor Angharad MR Gatehouse	Bitrophic and tritrophic effects of Bt Cry3A transgenic potato on beneficial, non-target, beetles	2007
Dr Evan Mulligan Dr Natalie Ferry Dr Gordon Port Professor Angharad MR Gatehouse	Comparing the impact of conventional pesticide and use of a transgenic pest-resistant crop on the beneficial carabid beetle Pterostichus melanarius	2006
Dr Natalie Ferry Dr Evan Mulligan Dr Gordon Port Professor Angharad MR Gatehouse	Prey-mediated effects of transgenic canola on a beneficial, non-target, carabid beetle	2006
Dr Natalie Ferry Dr Evan Mulligan Dr Kaveh Emami Professor Angharad MR Gatehouse	Impact of oilseed rape expressing the insecticidal serine protease inhibitor, mustard trypsin inhibitor-2 on the beneficial predator Pterostichus madidus	2005
Dr Evan Mulligan	Influence of Bt-transgenic pollen, Bt-toxin and protease inhibitor (SBTI) ingestion on development of the hypopharyngeal glands in honeybees	2005
Dr Natalie Ferry Dr Martin Edwards Dr Evan Mulligan Dr Kaveh Emami Adelina Simeonova Petrova et al.	Engineering resistance to insect pests	2004
Dr Martin Edwards Dr Natalie Ferry Dr Evan Mulligan Dr Kaveh Emami Adelina Simeonova Petrova et al.	The Role of Biotechnology in Crop Protection:Current Status and Future Perspectives	2004
Dr Evan Mulligan Dr Natalie Ferry Dr Gordon Port Professor Angharad MR Gatehouse	Impacts of transgenic crop technology upon the field slug Deroceras reticulatum (Muller)	2003